中华皮肤科杂志 ›› 2018, Vol. 51 ›› Issue (9): 704-707.doi: 10.3760/cma.j.issn.0412-4030.2018.09.023
钱玥彤,马东来
收稿日期:2017-09-29
修回日期:2017-10-30
出版日期:2018-09-15
发布日期:2018-08-30
通讯作者:
马东来
E-mail:mdonglai@sohu.com
Yue-Tong QIAN1,Dong-Lai MA
Received:2017-09-29
Revised:2017-10-30
Online:2018-09-15
Published:2018-08-30
Contact:
Dong-Lai MA
E-mail:mdonglai@sohu.com
摘要： Janus酪氨酸激酶（JAK）-信号转导及转录激活子（STAT）途径是一种细胞内信号传导通路，是多种细胞因子如白细胞介素（IL）、干扰素（IFN）及其他分子进行细胞膜到细胞核信号传导的重要途径，依赖于JAK?STAT途径的可溶性炎症介质参与了很多炎症性疾病的发病。因此，应用JAK抑制剂是治疗这类炎症性及免疫性疾病的新手段。目前临床上已用于治疗骨髓纤维化、真性红细胞增多症、类风湿性关节炎等疾病，并且越来越多的病例报告及临床研究证实，JAK抑制剂治疗特应性皮炎、斑秃、银屑病、白癜风等皮肤疾病也取得良好疗效……
钱玥彤 马东来. Janus酪氨酸激酶抑制剂在皮肤科的应用[J]. 中华皮肤科杂志, 2018, 51(9): 704-707.
Yue-Tong QIAN Dong-Lai MA. Application of Janus kinase inhibitors in dermatology[J]. Chinese Journal of Dermatology, 2018, 51(9): 704-707.
| ［1］ | Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis［J］. J Immunol Res, 2014,2014（3）:283617. doi: 10.1155/2014/283617.<br /> |
| ［2］ | Shreberk⁃Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review［J］. J Am Acad Dermatol, 2017,76（4）:745⁃753. doi: 10.1016/j.jaad.2016.12.004.<br /> |
| ［3］ | Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class［J］. J Am Acad Dermatol, 2017,76（4）:736⁃744. doi: 10.1016/j.jaad.2016.12.005.<br /> |
| ［4］ | Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo⁃controlled, phase III trials［J］. Br J Dermatol, 2015,173（4）:949⁃961. doi: 10.1111/bjd.14018.<br /> |
| ［5］ | Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate⁃to⁃severe chronic plaque psoriasis: a phase 3 randomised non⁃inferiority trial［J］. Lancet. 2015,386（9993）:552⁃561. doi: 10.1016/S0140⁃6736（14）62113⁃9.<br /> |
| ［6］ | Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403. <br /> |
| ［7］ | Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis［J］. Br J Dermatol, 2013,169（1）:137⁃145. doi: 10.1111/bjd.12266.<br /> |
| ［8］ | Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial［J］. BMC Dermatol, 2016,16（1）:15. doi: 10.1186/s12895⁃016⁃0051⁃4.<br /> |
| ［9］ | Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis［J］. J Am Acad Dermatol, 2012,67（4）:658⁃664. doi: 10.1016/j.jaad. 2011.12.018.<br /> |
| ［10］ | Udkoff J, Waldman A, Ahluwalia J, et al. Current and emerging topical therapies for atopic dermatitis［J］. Clin Dermatol, 2017,35（4）:375⁃382. doi: 10.1016/j.clindermatol.2017.03.010.<br /> |
| ［11］ | Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate［J］. J Am Acad Dermatol, 2015,73（3）:395⁃399. doi: 10.1016/j.jaad.2015.06.045.<br /> |
| ［12］ | Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial［J］. Br J Dermatol, 2016,175（5）:902⁃911. doi: 10.1111/bjd.14871.<br /> |
| ［13］ | Liu LY, Craiglow BG, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients［J］. J Am Acad Dermatol, 2017,76（1）:22⁃28. doi: 10.1016/j.jaad.2016. 09.007.<br /> |
| ［14］ | Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition［J］. Nat Med, 2014,20（9）:1043⁃1049. doi: 10.1038/nm.3645.<br /> |
| ［15］ | Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis［J］. JAMA Dermatol, 2016,152（4）:490⁃491. doi: 10.1001/jamadermatol.2015.4445.<br /> |
| ［16］ | Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib［J］. J Am Acad Dermatol, 2017,76（6）:1054⁃1060. doi: 10.1016/j.jaad.2017.02. 049.<br /> |
| ［17］ | Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.<br /> |
| ［18］ | Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA） ［J］. J Am Acad Dermatol, 2016,74（2）:370⁃371. doi: 10.1016/j.jaad.2015.09.073.<br /> |
| ［19］ | Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682. doi: 10.1016/j.jaad.2017.05.043.<br /> |
| ［20］ | Hornung T, Janzen V, Heidgen FJ, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib［J］. N Engl J Med, 2014,371（26）:2537⁃2538. doi: 10.1056/NEJMc1412997.<br /> |
| ［21］ | Vesely MD, Imaeda S, King BA. Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis［J］. JAAD Case Rep, 2016,3（1）:4⁃6. doi: 10.1016/j.jdcr.2016.09.008.<br /> |
| ［22］ | Damsky W, King BA. Idiopathic erythema multiforme: evidence of underlying Janus kinase⁃signal transducer and activator of transcription activation and successful treatment with tofacitinib［J］. JAAD Case Rep, 2016,2（6）:502⁃504. doi: 10.1016/j.jdcr.2016. 10.009.<br /> |
| ［23］ | Vincenti F, Silva HT, Busque S, et al. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients［J］. Am J Transplant, 2015,15（6）:1644⁃1653. doi: 10.1111/ajt.13181.<br /> |
| ［24］ | Samadi A, Ahmad Nasrollahi S, Hashemi A, et al. Janus kinase （JAK） inhibitors for the treatment of skin and hair disorders: a review of literature［J］. J Dermatolog Treat, 2017, 28（6）: 476⁃483. doi: 10.1080/09546634.2016.1277179.<br /> |
| [1] | 梁源 刘玲玲 王珊 赵作涛 马琳 向欣 顾恒 陈崑 王华 易红 陈谨萍 张金桃 姚志荣 郭一峰 陈戟 程颖 朱学骏. 0.03%他克莫司软膏长期间歇维持治疗儿童特应性皮炎的多中心随机对照临床研究[J]. 中华皮肤科杂志, 2019, 52(8): 519-524. |
| [2] | 路坦 王珊 王榴慧 李萍 舒虹 申春平 吴瑶 罗珍 缪丽敏 王红兵 焦磊 田晶 彭晓霞 赵牧童 刘盈 聂晓璐 马琳 何黎. 一种含青刺果油等提取物的润肤剂改善儿童特应性皮炎缓解期临床症状的多中心、随机、平行对照临床研究[J]. 中华皮肤科杂志, 2019, 52(8): 537-541. |
| [3] | 卢旭亚 徐强 李品川 张朝晖. 下肢痛性溃疡诊疗进展[J]. 中华皮肤科杂志, 2019, 52(7): 510-514. |
| [4] | 陈怡雯 苏婷 苏忠兰. 银屑病与STAT3[J]. 中华皮肤科杂志, 2019, 52(7): 502-505. |
| [5] | 李遇梅 张怡萱 刘莉萍. 诱导性多功能干细胞在皮肤科研究与应用的进展[J]. 中华皮肤科杂志, 2019, 52(7): 445-449. |
| [6] | 余丽娟 吕中法. JAK抑制剂治疗斑秃的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 343-346. |
| [7] | 周园 陈韡 王大光. 钳形甲的治疗进展[J]. 中华皮肤科杂志, 2019, 52(5): 364-367. |
| [8] | 肖易 陈丽萍 敬丹榕 粟娟 李濛 沈敏学 陈翔. 支付意愿在测量皮肤疾病负担中的意义与应用[J]. 中华皮肤科杂志, 2019, 52(4): 286-289. |
| [9] | 罗金成 陈曙光 刘文英 徐艳 宋志强. 自体全血注射对自体血清皮肤试验阳性的难治性慢性自发性荨麻疹患者嗜碱性粒细胞FcεRⅠ与CD63表达的影响[J]. 中华皮肤科杂志, 2019, 52(4): 241-247. |
| [10] | 雷杰豪 樊奇敏 陈荣 许爱娥. 白癜风患者窄谱中波紫外线治疗效果与光疗反应的关系及相关因素分析[J]. 中华皮肤科杂志, 2019, 52(4): 259-262. |
| [11] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018简版）[J]. 中华皮肤科杂志, 2019, 52(4): 223-230. |
| [12] | 翟寒月 宋益兴. 585 nm脉冲染料激光治疗儿童传染性软疣的临床观察[J]. 中华皮肤科杂志, 2019, 52(3): 195-197. |
| [13] | 中华医学会皮肤性病学分会红斑狼疮研究中心. 皮肤型红斑狼疮诊疗指南（2019版）[J]. 中华皮肤科杂志, 2019, 52(3): 149-155. |
| [14] | 汤顺利 方红. 雄激素性秃发的发病机制[J]. 中华皮肤科杂志, 2019, 52(3): 208-210. |
| [15] | 王刚. 皮肤科生物制剂的主要不良反应及对策[J]. 中华皮肤科杂志, 2019, 52(2): 77-80. |
|
